Impact of new antifungal breakpoints on antifungal resistance in Candida species

J Clin Microbiol. 2014 Mar;52(3):994-7. doi: 10.1128/JCM.03044-13. Epub 2014 Jan 8.

Abstract

We reviewed our antifungal susceptibility data for micafungin, anidulafungin, fluconazole, and voriconazole against Candida species and compared resistance rates determined by the previous and recently revised CLSI antifungal breakpoints. With the new breakpoints, resistance was significantly increased for micafungin (from 0.8% to 7.6%), anidulafungin (from 0.9% to 7.3%), and voriconazole (from 6.1% to 18.4%) against Candida glabrata. Resistance was also increased for fluconazole against Candida albicans (from 2.1% to 5.7%).

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antifungal Agents / pharmacology*
  • Antifungal Agents / therapeutic use
  • Candida / drug effects*
  • Candida / isolation & purification
  • Candidiasis / drug therapy
  • Candidiasis / microbiology*
  • Drug Resistance, Fungal*
  • Humans
  • Microbial Sensitivity Tests / methods
  • Microbial Sensitivity Tests / standards

Substances

  • Antifungal Agents